Synjardy® (empagliflozin/metformin) – Expanded indication
Boehringer Ingelheim announced the FDA approval of Synjardy (empagliflozin/ metformin) tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate.
Top